June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Dry Eye Disease Results in an Imbalance of Neuropeptides and Neurotrophins in the Cornea and Trigeminal Ganglion
Author Affiliations & Notes
  • Flavia Leao
    Ophthalmology, Tufts Medical Center, Boston, Massachusetts, United States
  • Victor G. Sendra
    Ophthalmology, Tufts Medical Center, Boston, Massachusetts, United States
  • Brendan Kenyon
    Ophthalmology, Tufts Medical Center, Boston, Massachusetts, United States
    Program in Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Deshea L Harris
    Ophthalmology, Tufts Medical Center, Boston, Massachusetts, United States
  • Pedram Hamrah
    Ophthalmology, Tufts Medical Center, Boston, Massachusetts, United States
    Ophthalmology, New England Eye Center, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Flavia Leao, None; Victor Sendra, None; Brendan Kenyon, None; Deshea Harris, None; Pedram Hamrah, None
  • Footnotes
    Support  NIH-R01- EY022695, NIH-R01- EY026963, Massachusetts Lions Eye Research Fund, Inc., and Tufts Medical Center Institutional Support, Research to Prevent Blindness Challenge Grant to the Department of Ophthalmology
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1319. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Flavia Leao, Victor G. Sendra, Brendan Kenyon, Deshea L Harris, Pedram Hamrah; Dry Eye Disease Results in an Imbalance of Neuropeptides and Neurotrophins in the Cornea and Trigeminal Ganglion. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1319.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : It has previously been demonstrated that dry eye disease (DED) results in decreased corneal nerve density. The aim of the current study was to evaluate if DED results in alterations of neuropeptides (NPs) and neurotrophins in the cornea and trigeminal ganglia (TG).

Methods : Adult 6-8-week-old C57BL/6N female mice were injected with 0.5mg of scopolamine hydrobromide and kept in a controlled environment chamber for 14 days and compared to control mice. Clinical evaluations included slit-lamp microscopy, tear secretion, corneal esthesiometry and challenge with [5M] saline. Nerve density was assessed by immunohistochemistry of corneal whole-mounts for βIII Tubulin and confocal microscopy. mRNA and proteins levels of 11 molecular targets of NPs and neurotrophins were assessed by qRT-PCR and ELISA for corneas and TG. A one-way ANOVA with Tukey’s multiple comparison was used to compare effects between groups.

Results : DED mice demonstrated decreased tear secretion (p≤0.0001) and increased corneal fluorescein staining compared to controls (p≤0.0001). Decreased corneal nerve densitywas measured in DED (78.2±2.8mm/mm2) compared to controls (142.5±13.7; p≤0.0001).A significant increase in paw wipe response was observed with 10 μL of [5M] salinein DED compared to controls 38.6 vs. 17.2 (p≤0.0001). Corneal qRT-PCR revealed decreased neurotrophin expression in DED compared to controls, with 3.1-fold decrease in NGF, 2.4-fold decrease in BDNF and 2.9-fold decrease in NT3 (all p<0.0001), which was confirmed at the protein level by ELISA (all p<0.0001). In addition, there was an upregulation of corneal Substance P (3.4-fold) and CGRP (2.5-fold) in DED compared to controls (p<0.0001 for both). In interestingly, there was downregulation of VIP (2.5-fold), PACAP (3.3-fold), Neurotensin (5.0-fold), Somatostatin (2.0-fold) and NPY (5.0-fold) (all p<0.01). In contrast TG of DED mice demonstrated 4.5-fold upregulation of NGF and 6.3-fold increase in NT-4/5 vs controls (p<0.0001). However, within the TG, only Substance P and Somatostatin were increased in DED by 1.7-fold and 2.2-fold respectively (both <0.05).

Conclusions : This study provides evidence of imbalance in corneal and TG neurotrophins and NPs in DED. A deeper understanding of the neurochemistry, trophic factors and nervous system may lead to improved treatments for DED.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×